Oncotelic Therapeutics
OTC: OTLCAgoura Hills, US · Delaware corporation
Find your way into Oncotelic Therapeutics
7 people in our graph share verified history with the Oncotelic Therapeutics team — schools, employers, funds. One of them is your warm intro.
James Chapmanunlockedknows SARAN SAUND · together at CSR (overlapped)
knows the team · via Knowles Corporation
×5knows the team · via CSR
Oncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
Founders & leadership
AM
ANTHONY MAIDAinExecutive
SA
SHAH AMITExecutive
SS
SARAN SAUNDinChief Business OfficerSaran Saund worked as a software engineer at Xerox PARC before co-founding PicoMobile, which was acquired by Marvell Semiconductor in 2008; he has since advised early-stage and Fortune 500 companies on technology applications and has worked on machine learning and neural network projects in genomics and other domains.
MM
Matthew M. LoarExecutive
VT
Vuong TrieuinCEO & Chairman
AS
Amit ShahinChief Financial OfficerAmit Shah is Chief Financial Officer of Oncotelic Therapeutics, a biopharmaceutical company developing oncology therapeutics. He brings expertise in pharmaceutical and biotechnology finance, SEC reporting and compliance, financial planning and analysis, and internal controls.
FU
Fatih UckuninChief Medical Officer/Advisor2022–2023Fatih M. Uckun holds M.D. and Ph.D. degrees from the University of Heidelberg and completed residency, fellowship, and postdoctoral training in pediatrics, hematology/oncology, and immunology at the University of Minnesota. He has over 30 years of experience in oncology and immuno-oncology therapeutics, served as a professor and director of the Biotherapy Institute at the University of Minnesota, held a faculty position in translational leukemia/lymphoma research at the University of Southern California, and has held executive roles in multiple biotechnology companies with regulatory expertise.
CP
Chulho ParkinChief Technology OfficerChulho Park is Chief Technology Officer at Oncotelic Therapeutics, a biopharmaceutical company developing oncology treatments. He has over 25 years of experience in biologics and chemical drug research and development across academic, biotech, and pharmaceutical organizations, including leadership roles in developing therapeutic antibodies and small molecule drugs.
SF
Seymour FeinChief Medical Officer
WD
William D. SchwietermanNamed on SEC filing
DR
Donald R. ReynoldsNamed on SEC filing
SC
Simon C. PedderNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$33.5M disclosed across 6 of 7 rounds · 2018–2026
▶$711.8KraisedJul 2026 · 33 investors · BiotechnologyRule 506(b)
▶$711.8KraisedJul 2026 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- VUONG TRIEUExecutive Officer, Director
- STEVEN KINGDirector
- ANTHONY MAIDAExecutive Officer, Director
- SHAH AMITExecutive Officer
- SEYMOUR FEINExecutive Officer
- SARAN SAUNDExecutive Officer
- Offering amount
- $711.8K
- Amount sold
- $711.8K
- Placement agents
- N.A.
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$275KraisedDec 2025 · 4 investors · BiotechnologyRule 506(b)
▶$275KraisedDec 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- VUONG TRIEUExecutive Officer, Director
- Offering amount
- $12.5M
- Amount sold
- $275K
- Minimum investment
- $25K
- Sales commissions
- $1.9M
- Proceeds to insiders
- $10.6M
- Placement agents
- J.H. DARBIE & CO
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MofferedJul 2023 · 15 investors · BiotechnologyRule 506(b)
▶$5MofferedJul 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vuong TrieuExecutive Officer, Director
- Saran SaundExecutive Officer
- Seymour FeinExecutive Officer
- Anthony MaidaExecutive Officer
- Amit ShahExecutive Officer
- Offering amount
- $5M
- Minimum investment
- $25K
- Sales commissions
- $650K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedAug 2020 · 24 investors · BiotechnologyRule 506(b)
▶$2MraisedAug 2020 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vuong TrieuExecutive Officer, Director
- Amit ShahExecutive Officer
- Chuho ParkExecutive Officer
- Offering amount
- $5M
- Amount sold
- $2M
- Minimum investment
- $50K
- Sales commissions
- $256K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$600KraisedMay 2019 · 4 investors · BiotechnologyRule 506(b)
▶$600KraisedMay 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fatih UckunExecutive Officer
- Chulho ParkExecutive Officer
- Matthew LoarExecutive Officer
- William SchwietermanDirector
- Vuong TrieuExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $600K
- Minimum investment
- $38K
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$27MraisedMay 2019 · 26 investors · BiotechnologyRule 506(b)
▶$27MraisedMay 2019 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fatih UckunExecutive Officer
- Matthew LoarExecutive Officer
- Vuong TrieuExecutive Officer, Director
- Chulho ParkExecutive Officer
- William SchwietermanDirector
- Offering amount
- $27M
- Amount sold
- $27M
- Sales commissions
- $545K
- Placement agents
- Stout Risius Ross Advisors, LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedApr 2018 · 38 investors · BiotechnologyRule 506(b)
▶$2.9MraisedApr 2018 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William D. SchwietermanExecutive Officer, Director
- Matthew M. LoarExecutive Officer
- Donald R. ReynoldsDirector
- Simon C. PedderDirector
- Bobby W. Sandage, Jr.Director
- David J. ChaplinExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $2.9M
- Minimum investment
- $25K
- Sales commissions
- $400K
- Placement agents
- Divine Capital Markets LLC
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Oncotelic Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Oncotelic Announces New Convertible Note Financing Agreement - The Globe and Mailtheglobeandmail.com · Aug 2026
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present at OTCQB Virtual Investor Conference - InvestorWire (IW)investorwire.com · Aug 2026InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Brings AI and Robotics Together in New Platform - InvestorWire (IW)investorwire.com · Jul 2026
Oncotelic Therapeutics (OTLC) grants 1,500 performance RSUs to directorstocktitan.net · Jul 2026Frequently asked questions
- What does Oncotelic Therapeutics do?
- Oncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
- How much funding has Oncotelic Therapeutics raised?
- Oncotelic Therapeutics has disclosed $33.5M raised across 6 of its 7 known rounds.
- Where is Oncotelic Therapeutics headquartered?
- Oncotelic Therapeutics is headquartered in Agoura Hills, US.